Author
Not all lobbying campaigns are problematic — the goal should be for regulators to leverage industry insights while maintaining independence in decision-making.
There is little consensus in defining “psychedelic.” Yet, research on and access to these substances hinges on what gets included under this umbrella.
A combination of high demand and a patent monopoly has created a perfect storm of profitability for Janssen’s Spravato.
The most effective way to change peoples’ opinions is to highlight the success stories of those who have tried psychedelics.
Funding for psychedelic research may increasingly rely on nonprofit and commercial partnerships.
Psychedelics hold promise to address an array of conditions, but potential benefits may be stratified along the lines of socioeconomic status.
